Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for prevention of antibody-mediated rejection after sensitized deceased-donor kidney transplant
ACTRN12612000333819Phase 2Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 2, open-label trial of eculizumab in kidney allograft rejection and humoral rejection (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Week 9 post-transplant composite treatment failure rate and Safety and efficacy of eculizumab to prevent antibody-mediated rejection. Started Nov 2012; status: recruiting.
02
Drugs
eculizumab
03
Conditions
kidney allograft rejectionhumoral rejection
Beyond the preview
Go deeper on ACTRN12612000333819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000333819.